AmpliPhi Biosciences names Igor Bilinsky COO
Dr. Bilinsky brings to AmpliPhi nearly two decades of experience as a life sciences company executive and consultant, serving public and private companies.
Prior to joining AmpliPhi, Dr. Bilinsky was General Manager of Immuno-Oncology and Senior Vice President of Special and Research Operations at Ignyta, Incorporated.
Previously he was Senior Vice President of Corporate Development at Vical Incorporated and was Vice President, Business Development and Special Operations at Halozyme Therapeutics.
Earlier in his career, Dr. Bilinsky was CEO of Androclus Therapeutics. At The Boston Consulting Group, he served in positions of increasing responsibility as a management consultant, project leader and ultimately as principal in the healthcare practice, where he advised companies in the biotechnology, pharmaceutical and life science industries on business strategy, operational performance and mergers and acquisitions.
Dr. Bilinsky received a B.S. in physics from the Moscow Institute of Physics and Technology and a Ph.D. in physics from the Massachusetts Institute of Technology.
He succeeds Wendy S. Johnson, who served as AmpliPhi’s interim COO since September 2014 and continues to serve on AmpliPhi’s board of directors. ■
LATEST MOVES FROM California
- ChromaDex appoints Steven Rubin to board
- Impax Laboratories appoints Paul M. Bisaro as CEO
- Retrophin names John A. Orwin to board
- Intel appoints two to board
- Walt Disney Company extends CEO's contract to 2019
More inside POST
Gordmans Stores files for bankruptcy Companies